Je was op zoek naar: calcineurin (Engels - Sloveens)

calcineurin inhibitors, atc code:
zaviralci kalcinevrina, oznaka atc:

for dosing recommendations with calcineurin inhibitors see section 4.5.
za priporočila o odmerjanju z zaviralci kalcinevrina glejte poglavje 4.5.

protopy contains the active substance tacrolimus, a calcineurin inhibitor.
protopy vsebuje zdravilno učinkovino takrolimus, ki zavira kalcinevrin.

for dosing recommendations with calcineurin inhibitors refer to section 4.5.
za priporočila o odmerjanju z zaviralci kalcinevrina glejte poglavje 4.5.

calcineurin inhibitors has been associated with an increased risk of developing lymphomas and skin malignancies.
dolgotrajno sistemsko izpostavljenost intenzivni imunosupresiji, po sistemski uporabi zaviralcev kalcinevrina, spremljalo večje tveganje za limfome in malignome na koži.

pimecrolimus is a calcineurin inhibitor approved as cream formulation at a 1% concentration.
pimekrolimus je zaviralec kalcineurina in je bil kot zdravilo odobren v obliki kreme v 1% koncentraciji.

au lymphoma is a recognised and listed adverse effect for systemically administered calcineurin inhibitor products.
a vsebujejo zaviralce kalcineurina.

pharmacotherapeutic group: immunosuppressants, calcineurin inhibitors, atc code: l04ad02 mechanism of action
farmakoterapevtska skupina: imunosupresivi, zaviralci kalcinevrina, oznaka atc: l04ad02 mehanizem delovanja

the safety and efficacy of conversion from calcineurin inhibitors to rapamune in maintenance renal transplant patients have not been established.
varnosti in učinkovitosti prehoda z zaviralcev kalcinevrina na zdravilo rapamune pri bolnikih na vzdrževalnem zdravljenju po presaditvi ledvice niso ugotovili.

pimecrolimus binds with high affinity to macrophilin-12 and inhibits the calcium-dependent phosphatase calcineurin.
pimekrolimus se z veliko afiniteto veže na makrofilin- 12 in zavira od kalcija odvisno fosfatazo kalcinevrin.

prolonged systemic exposure to intense immunosuppression in transplant patients following systemic administration of calcineurin inhibitors has been associated with an increased risk of developing lymphomas and skin malignancies.
dolgotrajno sistemsko izpostavljanje močni imunosupresiji pri bolnikih, pri katerih je bila opravljena presaditev, po sistemskem dajanju zaviralcev kalcineurina je bilo povezano s povečanim tveganjem za razvoj limfomov in malignih obolenj kože.

in transplant patients, prolonged systemic exposure to intense immunosuppression following systemic administration of calcineurin inhibitors has been associated with an increased risk of developing lymphomas and skin malignancies.
pri bolnikih s presadki je dolgotrajno sistemsko izpostavljenost intenzivni imunosupresiji, po sistemski uporabi zaviralcev kalcinevrina, spremljalo večje tveganje za limfome in malignome na koži.

the concomitant use of sirolimus with a calcineurin inhibitor may increase the risk of calcineurin inhibitor-induced hus/ttp/tma.
sočasna uporaba sirolimusa z zaviralcem kalcinevrina lahko poveča tveganje za hemolitično-uremični sindrom/trombotično trombocitopenično purpuro/trombotično mikroangiopatijo (hus/ttp/tma), izzvanimi z zaviralcem kalcinevrina.

the use of mifamurtide concurrently with ciclosporin or other calcineurin inhibitors is contraindicated due to their hypothesised effect on splenic macrophages and mononuclear phagocytic function (see section 4.3).
uporaba mifamurtida skupaj s ciklosporinom ali z drugimi zaviralci kalcinevrina je kontraindicirana zaradi njihovega domnevnega vpliva na makrofage v vranici ali funkcijo mononuklearnih fagocitov (glejte poglavje 4.3).

hypersensitivity to the active substance or to any of the excipients listed in section 6.1. concurrent use with ciclosporin or other calcineurin inhibitors (see section 4.5).
preobčutljivost na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1. sočasna uporaba s ciklosporinom ali z drugimi zaviralci kalcinevrina (glejte poglavje 4.5).

an unacceptably high frequency of ptld was seen in a paediatric clinical transplant study when full dose rapamune was administered to children and adolescents in addition to full dose calcineurin inhibitors with basiliximab and corticosteroids (see section 4.8).
v pediatrični klinični študiji po presaditvi so opažali nesprejemljivo visok delež ptld, ko so zdravilo rapamune v polnem odmerku dajali otrokom in mladostnikom poleg zaviralcev kalcinevrina, basiliksimaba in kortikosterodiov v polnih odmerkih (glejte poglavje 4. 8).

the concomitant use of rapamune with a calcineurin inhibitor may increase the risk of calcineurin inhibitor-induced haemolytic uraemic syndrome/ thrombotic thrombocytopenic purpura/ thrombotic microangiopathy (hus/ ttp/ tma).
sočasna uporaba zdravila rapamune z zaviralci kalcinevrina lahko poveča tveganje za nastanek hemolitično uremičnega sindroma / trombotične trombocitopenične purpure/ trombotične mikroangiopatije( hus/ ttp/ tma), induciranih z zaviralci kalcinevrina.